Search Results 821-830 of 18067 for Alopecia

1. Jessica's Story - Mayo Clinic

   An error occurred, please try again later. Copy for customer care: session ID undefined. Try again. Share · Tweet . VID-20466619. Home; Jessica's Story ...

2. A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer - Mayo Clinic

   Alopecia;; Neuropathy, which must have resolved to ≤ Grade 2;; Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of ...

3. Mayo Clinic

   I've been on staff at the Mayo Clinic since 1997 and my whole career has really been focused on treating cancer. I'm Dr. Steven Alberts.

4. Study to Evaluate CCS1477 in Haematological Malignancies - Mayo Clinic

   With the exception of alopecia, and CTCAE Grade 2 neuropathy, any unresolved toxicities from prior therapy > Grade 1 at the time of starting study treatment.

5. Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for Locally Advanced or Metastatic ER+/HER2− Breast Cancer - Mayo Clinic

   ... alopecia and Grade 2 peripheral neuropathy before study entry. A washout period of at least 21 days is required between last chemotherapy dose and entry ...

6. Brightcove-Orthopedic surgery home

   Cedric Ortiguera, M.D., Orthopedic Surgery, Mayo Clinic: So when patients come here to Mayo, I think they know that they're going to get the right treatment ...

7. A Study to Evaluate DS-8201a Combined with Olaparib in HER2-Expressing Cancers with Expansion in Endometrial Cancer Patients Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer - Mayo Clinic

   Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to grade ≤ 1 or baseline.

8. Study to Determine the Accuracy of a New Venous Air Plethysmograph in People with Normal, Incompetent, and Obstructed Venous Hemodynamics. - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

9. A Study to Evaluate Abemaciclib to Treat Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration - Mayo Clinic

   0] Grade ≤1) from the acute effects of chemotherapy (except for residual alopecia or Grade 2 peripheral neuropathy) prior to enrollment, or other toxicity ...

10. A Study to Evaluate the Safety, Tolerance and Anti-tumor Activity of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Non-Hodgkin Lymphoma - Mayo Clinic

    ... alopecia or toxicities from prior anticancer therapy that are considered irreversible (defined as having been present and stable for > 4 weeks) which may be ...